Amgen Arrives

Langreth, Robert
January 2006
Forbes Asia;1/9/2006, Vol. 2 Issue 1, p20
The article considers the efficacy of Amgen's drug panitumumab in reducing cancer progression. In November 2006, the Thousand Oaks, California company gained big win, when a final-stage test of advanced colon cancer patients found that the drug panitumumab reduced the rate of cancer progression by 46 percent. While hardly a cure, the drug may avoid the allergic reaction sometimes seen with Erbitux, made by Bristol-Myers Squibb and Imclone Systems.


Related Articles

  • Amgen: panitumumab speeding towards approval.  // PharmaWatch: Biotechnology;Jul2006, Vol. 5 Issue 7, p11 

    The article discusses the biologic license application of Amgen Inc. for its monoclonal antibody epidermal growth receptor inhibitor, panitumumab, which has been accepted and granted a priority review status by the U.S. Food and Drug Administration (FDA). The firm hopes to obtain market approval...

  • Amgen: Vectibix disappoints in colorectal cancer but hope remains.  // PharmaWatch: Monthly Review;Dec2009, Vol. 8 Issue 12, p8 

    The article reports on the failure of Vectibix drug which was tested by Amgen Inc. for the treatment of colorectal cancer. The failure was a setback as the drug earlier showed positive results and better overall survival than Erbitux, a similar monoclonal antibody. It mentions that Amgen may...

  • Amgen's Aranesp disappointing in breast cancer study.  // PharmaWatch: Cancer;Jan2008, Vol. 7 Issue 1, p9 

    The article reports on the results of a Phase III study conducted by Amgen Inc. for its Aranesp drug in the treatment of breast cancer. In a study of 733 neoadjuvant breast cancer patients, it showed numerically more deaths and tumor progression events on the Aranesp arm compared with the...

  • ASCO ROUNDUP.  // BioWorld Today;6/3/2008, Vol. 19 Issue 107, p6 

    This article deals with the Phase II data presented by Amgen Inc. showing that 71 percent of denosumab-treated patients achieved the primary endpoint of urinary N-telopeptide (uNTx) levels less than 50 at week 13, and that the drug also induced suppression of uNTx levels faster than intravenous...

  • Amgen up on drug trial result. Investor's Business Daily // Investors Business Daily;3/18/2014, pA02 

    The biotech said that a late-stage trial of its cholesterol drug evolocumab met its primary endpoint. The trial tested the potency of evolocumab in lower LDL (or "bad") cholesterol in patients with homozygous familial hypercholesterolemia, a rare genetic disorder that affects 1 mil people....

  • Amgen reports positive results from Phase III bone metastases trial.  // PharmaWatch: Biotechnology;Jul2010, Vol. 9 Issue 7, p13 

    The article reports that biotechnology company Amgen Inc. has announced positive results from Phase III bone metastases trial in the U.S.

  • AMGEN. Investor's Business Daily // Investors Business Daily;10/13/2015, pA02 

    The article reports on a positive clinical trial data issued by American biopharmaceutical firm Amgen Inc. for its romosozumab, a drug for postmenopausal women with low bone mass.

  • Amgen, Takeda's Lung Cancer Drug Stumbles in Phase III. Shaffer, Catherine // BioWorld Today;3/31/2011, Vol. 22 Issue 62, p2 

    This article reports on the release of top-line results of a Phase III trial of a VEGF inhibitor, motesanib, for nonsquamous non-small-cell lung cancer (NSCLC) by Amgen Inc. and Takeda Pharmaceutical Co. Ltd. in 2011. Both companies expressed disappointment regarding the results. The trial...

  • Vectibix Disappoints in Head/Neck Cancer Trial.  // Bioworld Week;8/16/2010, Vol. 18 Issue 33, p5 

    The article reports on the failure of the colorectal cancer drug Vectibix from Amgen Inc. in the Phase III trial in head and neck cancer on August 11, 2010.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics